Tharimmune is engaged in the development of therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treating cancers. Co.'s product candidate is HSB-1216, an IMCD modulator, targeting solid tumors. Co.'s HSB-888, is a dual-loaded IMCD inducer coupled with its anthracycline analogue. Co.'s HSB-510 is a bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6. Co. owns HSB-114, which is a immunotherapeutic agent that delivers tumor necrosis factor-alpha gene into cancer cells. The THAR average annual return since 2022 is shown above.
The Average Annual Return on the THAR average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether THAR average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the THAR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|